DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of DBV Technologies in a research note on Wednesday, February 21st.

DBV Technologies Stock Down 1.4 %

Shares of NASDAQ:DBVT opened at $0.76 on Wednesday. DBV Technologies has a 12 month low of $0.65 and a 12 month high of $2.37. The company’s 50-day moving average price is $0.84 and its two-hundred day moving average price is $0.96. The firm has a market cap of $145.74 million, a P/E ratio of -1.94 and a beta of 0.76.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.10. The company had revenue of $8.88 million for the quarter, compared to analyst estimates of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. During the same quarter last year, the firm earned ($0.23) EPS. As a group, equities analysts predict that DBV Technologies will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of DBVT. Landscape Capital Management L.L.C. bought a new position in DBV Technologies during the 3rd quarter worth approximately $94,000. Optiver Holding B.V. boosted its stake in DBV Technologies by 595.2% during the 3rd quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock worth $374,000 after acquiring an additional 235,337 shares during the last quarter. BNP Paribas Arbitrage SNC boosted its stake in DBV Technologies by 74.2% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 39,034 shares of the company’s stock worth $74,000 after acquiring an additional 16,626 shares during the last quarter. Envestnet Asset Management Inc. bought a new position in DBV Technologies during the 3rd quarter worth approximately $67,000. Finally, Two Sigma Investments LP boosted its stake in DBV Technologies by 80.9% during the 3rd quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock worth $64,000 after acquiring an additional 16,066 shares during the last quarter. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.